NCT00005859

Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma

Phase I/II Trial of R115777 in Patients With Recurrent Malignant Glioma

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 136 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent or progressive malignant glioma.

Detailed description

OBJECTIVES: * Determine the maximum tolerated dose of tipifarnib in patients with recurrent or progressive malignant glioma receiving enzyme-inducing antiepileptic drugs. (Stratum II in the phase I portion of this study closed to accrual effective 07/16/2001.) (Phase I completed effective 10/2/2001.) (Phase II open only to patients requiring resection and who provide surgical tissue samples \[effective 3/13/2003\].) * Define the safety and pharmacokinetic profile of this drug in this patient population. * Assess for evidence of antitumor activity of this drug in these patients. * Assess for evidence of inhibition of farnesyl protein transferase (FTase) on peripheral blood monocytes as a surrogate endpoint of effective biologic activity of this drug in these patients. * Determine the efficacy of this drug as measured by 6-month progression-free survival and objective tumor response in these patients. * Evaluate further the safety profile of this drug in these patients. * Correlate treatment response with inhibition of FTase in peripheral blood monocytes in patients treated with this drug. OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to their pretreatment medications (not receiving enzyme-inducing antiepileptic drugs \[EIAEDs\] vs receiving EIAEDs with or without steroids). Patients receive oral tipifarnib twice daily on days 1-21. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression. * Phase I (completed 10/2/2001): Cohorts of 3-6 patients from stratum II receive escalating doses of tipifarnib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. (Stratum II in the phase I portion of this study closed to accrual effective 07/16/2001.) * Phase II (open only to patients requiring resection and who provide surgical tissue samples \[effective 3/13/2003\]): Once the MTD is determined, additional patients with glioblastoma multiforme from stratum II are accrued to receive treatment with tipifarnib at the recommended phase II dose. Patients are followed every 2 months for 1 year, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months until progression. Patients are then followed every 4 months thereafter. PROJECTED ACCRUAL: Approximately 30 patients (15 per stratum) will be accrued for the phase I portion of this study within 10 months. (Stratum II in the phase I portion of this study closed to accrual effective 07/16/2001.) (Phase I completed effective 10/2/2001.) A total of 24 patients with glioblastoma multiforme from stratum II will be accrued for the phase II portion of this study. (Phase II open only to patients requiring resection and who provide surgical tissue samples \[effective 3/13/2003\].)

Conditions

• Brain and Central Nervous System Tumors

Interventions

Type	Name	Description
DRUG	tipifarnib

Timeline

• Start date: 2000-05-16
• Primary completion: 2005-07-01
• Completion: 2006-08-01
• First posted: 2003-01-27
• Last updated: 2018-06-26

Locations

11 sites across 1 country: United States

Regulatory

• FDA-regulated drug study